MULTIPLE SCLEROSIS RESEARCH
THEORIES AND
CLINICAL TRIALS
AASTROMREPLICELL
7/98 AastromReplicell(TM) Cell Production System for Stem Cell therapies in the
treatment of cancer, autoimmune and other diseases.
ACYCLOVIR
3/96 Acyclovir treatment of
relapsing-remitting multiple sclerosis. A randomized, placebo-controlled,
double-blind study.
ALLERGY
2/97 IgG4, a subclass of the IgG class
of antibody, displays many characteristics that support its physiological
function as a potential IgG4 allergen-specific blocking antibody.
AMALGAM
The safety of dental Amalgam restorations has been
challenged with assertions that mercury released from amalgam produces mercury
poisoning, and is thus responsible for diverse symptoms of impaired health as
well as disease states such as Multiple Sclerosis (MS).
ANERGEN
Anergen, Inc. (NASDAQ:ANRG)announced today that the results of
Anergen's randomized, double-blind, placebo-controlled dose escalation study in
secondary chronic progressive multiple sclerosis suggest that the Company's AnergiX therapeutic (AG284 for
multiple sclerosis) is safe and well tolerated. Results of the study were
presented at the annual meeting of America's Committee for Treatment and
Research in Multiple Sclerosis (ACTRIMS).
ANTEGREN®
7/99 Elan announced Preliminary Results of a Phase
II clinical study evaluating Antegren(R) (natalizumab), a humanized monoclonal
antibody, in the treatment of acute exacerbation in patients with multiple
sclerosis ("MS")
Antegren® Clinical
Trials Under Way.
DUBLIN, IRELAND. Elan Corporation, announced today that its humanized
monoclonal antibody Antegren®,
has met their internal clinical criteria to advance in development as a
potential treatment for patients with multiple sclerosis.
ANTIBODIES (INTERFERON)
5/97 It was noted that all type 1 Interferons (IFN-A and IFN-B)
are naturally occurring cytokines, and that antibodies to IFN-A and IFN-B can be
detected in the general, previously-untreated population.
10/99 The Avonex
Alliance and Personal
Stories
3/3/99 CAMBRIDGE, MA (March 1, 1999) -- Biogen, Inc.
(NASDAQ/BGEN) said that today’s U.S. Food and Drug Administration (FDA) ruling
Upholding Orphan Drug
exclusivity for the Company’s AVONEX® (Interferon beta-1a), as
well Berlex Laboratories’ Betaseron® (Interferon beta-1b), is in the
best interests of the entire multiple sclerosis community and a safeguard for
future drug development.
3/1/99 The incentive of Orphan Drug
exclusivity has enabled Biogen to fund important new
research on AVONEX and other products. Biogen reinvests about 30% of revenues
into research for new compounds, many of which have potential to provide new
treatment options for people with MS
The Avonex Difference. AVONEX® is one
of two forms of interferon beta available to treat MS in the United States (the
other is Betaseron® (Interferon beta-1b)). AVONEX® differs from Betaseron® in
its indication, its molecular structure, and its manufacturing process and
AVONEX® also requires less frequent dosing.
The good
news is that now you can do something to help maintain your current level of
functioning. Avonex is a
once-a-week therapy that can help slow the progression of disability in
relapsing forms of MS.
Clinical
Trials
The Avonex Support Line 1-800-456-2255 will be happy to answer any
questions you may have.
10/13/99 COPAXONE(R) and Betaseron(R)
significantly reduced relapses in patients with relapsing-remitting
multiple sclerosis, while patients on Avonex(R) failed to show a
statistically significant therapeutic effect in this 12-month treatment
study.
10/19/98 Richmond, CA Adding to the most
comprehensive array of support programs for people with multiple sclerosis,
Berlex Laboratories, Inc. today announced the introduction of the Beta AdvantageÔ program – a new service that provides free injection
supplies to patients on therapy with BetaseronÒ
(Interferon beta-1b) for SC injection.
7/98 Free for
Betaseron users!!
6/98 With the presentation of the results of these data at
ENS, the
investigators stated that Betaseron
® is the only therapy likely to have shown in a clinical trial, the delay of
progression of disability in secondary progressive MS. The FDA will review these
data to confirm these findings.
02/10/98 News Release: Berlex Laboratories, Inc. today announced the
initial findings of a large European clinical trial which found that Betaseron (Interferon beta-1b)
slowed the progression of disability in patients with secondary progressive
multiple sclerosis (MS).
Long-Term Clinical
Experience with Betaferon Confirms Excellent Efficacy and
Tolerability
For questions, problems or information regarding multiple sclerosis or
Betaseron, call their MS Pathways Hotline at: 1-800-788-1467
5/97 MRI Data
regarding Betaseron.
12/96 Interferon Enhances
Cognition In MS.
BLADDER STUDIES
8/13/98 Just as a cardiac pacemaker helps maintain a steady heartbeat,
a new Bladder Pacemaker
helps men and women with debilitating bladder problems regain control of this
vital function, according to UCSF Stanford Health Care physicians, who pioneered
the technology.
2/97 Use of a bladder neck support Prosthesis is a safe and effective
treatment for women with stress or mixed incontinence according to a
study.
1/97 Desmopressin An
Effective Treatment For MS-Related Nocturia
9/17/96 Electrical
Stimulation "Promising" for MS-Associated Urinary Incontinence.
BLOOD BRAIN BARRIER
10/96 Technical: Research data on the BBB.
BONE MARROW
11/17/97 Some researchers believe the symptoms of multiple sclerosis
begin in the Bone marrow, the
base camp of the immune system, where many defensive cells are
formed.
1/7/97 UDATE "Connie
Lieske, 49, the first American to receive a bone marrow transplant to treat MS
died yesterday, about seven months after undergoing the pioneering
procedure."
10/2/96 A physician-researcher at the Medical College of Wisconsin is
about to try Bone Marrow
Transplants as a potential cure for multiple sclerosis, one of the first
such attempts in the United States.
BRAIN
Characterization of Differences between multiple
sclerosis and normal
brain: a global magnetization transfer
application.
BRAIN CELL TRANSPLANT
In an experiment that offers hope to patients with multiple sclerosis
and similar disorders, scientists have managed to get transplanted brain cells
to disperse and travel widely throughout the brain,
according to a report in
this month's Annals of Neurology, the scientific journal of the American
Neurological Association and the Child Neurology Society.
BREATHING
6/99 To investigate whether the localization of multiple sclerosis
(MS), the duration of the disease, and the level of neurologic functioning in
patients with MS predispose them to disturbed Breathing
Control.
CHLAMYDIA PNEUMONIA
NASHVILLE, TN -- July 2, 1999 -- Could a common bacterium be involved
in the development of multiple sclerosis? In this month's Annals of Neurology,
researchers report finding evidence of the bacterium Chlamydia pneumoniae in all the
multiple sclerosis (MS) patients in their study.
Toronto (April 23, 1999) An agent that causes
respiratory tract infections
such as community-acquired pneumonia, called chlamydia pneumonia, may be
a factor in the development of multiple sclerosis (MS) in some
patients, according to a study released during the American Academy
of Neurology 51st Annual Meeting April 17-24 in
Toronto.
CLADRIBINE©
1/25/99 18-month, placebo-controlled, double-blind study to
evaluate Cladribine in the
treatment of 52 patients with relapsing-remitting multiple
sclerosis.
Clinical trial results for Cladribine and an UPDATE: 10/96
See Medication
page.
CLINICAL TRIALS (MULTIPLE
TOPIC)
MS
Center, Georgetown University
1/99 Clinical
Trials for Multiple Sclerosis
Multiple Sclerosis Clinical Research
Centers
12/96 Diaminopyridine
Improves Leg Strength
Multiple Sclerosis Clinical
Update, December 8, 1996, NYC.
Calcium and vitamin D3 help prevent loss of Bone Mineral Density in patients
taking low-dose corticosteroids.
Clinical trials on
ultraviolet radiation, altered beta-adrenergic, chimeric anti-CD4, 2 CD4, 2CDA
and Copolymer.
See Medication
page.
COGNITION
The purpose of this Study was to illustrate how
cognitive functioning evolves over time in patients with multiple
sclerosis.
COPAXONE ®(COP-1)
3/1/99 Clinical
Trials announced.
9/98 Teva Marion Partners, maker of COPAXONE®, has been making false
statements about the drug’s abilities and effects, according to the U. S. Food
& Drug Administration (FDA). A warning letter was sent in late August
to Teva Marion Partners, ordering the company to stop advertising the drug as
able to slow, prevent or reverse the progression of MS.
Copaxone now
available.
DIAGNOSTIC TESTS
"Black holes" on an
MRI
DIET / NUTRITION
12/5/97 Promising Fatty
Acid Research Leads To MS Clinical Trial
1/97 An epidemiologic study has been performed on the relation between
the mortality rates from multiple sclerosis for the period 1983-1989 obtained
for 36 countries, Dietary Fat
, and latitude.
DRUG TRIALS
6/97 Multi-center trial of a monoclonal antibody treatment, Hu23F2G, for acute
exacerbations...people with MS needed.
ELECTROMAGNETIC TREATMENT -- PICO
TELSA
Abstracts (Just for
general reading....not proven or backed by multiple scientific or clinical trial
studies)
ELIPRODIL
1/99 Eliprodil appears to help repair the
Nerve Demyelination associated with Multiple Sclerosis, researchers
report
ENZYME
8/96 Scientists identify key Enzyme involved in autoimmune
disease.
6/15/96 Jerusalem. A key Enzyme that acts as a suicide weapon
causing cells to self-destruct has been discovered according to the Weizman
Institute of Science.
EPIDEMIOLOGY
11/98 Among some 7500
respondents with known place of birth who had completed a nationwide
questionnaire survey for multiple sclerosis (MS) in France in 1986, there were
260 born in former French North Africa (Algeria, Morocco, Tunisia).
ESTRIIOL
4/29/99
Estriol
ameliorates autoimmune demyelinating disease: implications for multiple
sclerosis.
EYE
National EYE Institute.....Clinical
Trials See also Vision on Page 2
of Research
12/97 Optic Neuritis Clinical Trial
FATIGUE
12/98 The cause of Chronic Fatigue syndrome (CFS) is
unknown. With respect to factors perpetuating fatigue, on the other hand, a
model has been postulated in the literature in which behavioral, cognitive, and
affective factors play a role in perpetuating fatigue. In the present study,
this hypothesized model was tested on patients with CFS and on fatigued patients
with multiple sclerosis (MS).
GANGLIOSIDES
When a Molecular Factor
normally found in the nervous system is damaged or missing, nerve cells in the
brain and body begin to degenerate, according to a new study in
mice.
GENERAL
12/98 Information on the
Myelin Project, Neural Stem Cells, Gene Therapy and more.
2/97 In an experimental murine model of Autoimmune Neuritis, high doses of
the recombinant myelin protein P2 had a pronounced beneficial
effect.
1/97 IL-12 Responsible For Excess Interferon-gamma In Progressive
MS
Dec 19, 1996 Scientists have found some hints that an Experimental approach to treating
multiplesclerosis may actually make the disease worse.
11/96 Abstract: Gliotoxic factor and multiple
sclerosis
10/96 Circulating
L-selectin in multiple sclerosis patients with active, gadolinium-enhancing
brain plaques. March 96
10/96 Circulating
Antibodies directed against conjugated fatty acids in sera of patients with
multiple sclerosis. March 96
10/96 Heat Shock Protein
July-96
8/96 Multiple Sclerosis
is on the increase.
8/96 Bacterial Toxin
Prevents Autoimmune Disorder in Rats.
7/24/96 The IFN pregnancy recognition hormone IFN-tau blocks both development and
superantigen reactivation of experimental allergic encephalomyelitis without
associated toxicity.
Encapsulated-Cell Treatment
Study
Multiple SclerosisResearch
Highlights from NINDS.
8/96 I am interested in documenting instances of patients with both
multiple sclerosis and other autoimmune diseases, of any type. SLE, RA,
Phemphigus, IDDM, etc. This can be either anecdotal or published.
EMAIL: kbecker@nchgr.nih.gov
Kevin G. Becker Ph.D. National Center for Human Genome Research NIH,
Bethesda, MD 20892
GGF2
12/98 ``Cambridge NeuroScience and its academic collaborators have
generated impressive data demonstrating the unique mechanism by which GGF2 stimulates the remyelination of
nerve cells,'' said David Lowe, Ph.D., head of CNS research at Bayer. ``The
companies have worked together in developing a manufacturing process for the
molecule.''
GENETICS
3/98 ST. PAUL, MN -- March 23, 1998 -- A new study helps determine the
risk of developing multiple sclerosis (MS) for SIBLINGS of MS patients. The
study is published in this month’s issue of Neurology.
2/97 The Multiple Sclerosis Scientific Research Foundation has
announced funding to continue the landmark Canadian Collaborative Project on Genetic Susceptibility in Multiple
Sclerosis.
11/96 Abstract:Twin
Study. Review of the contribution of twin studies in the search for
non-genetic causes of multiple sclerosis
10/96 DR2/DQw1
Inheritance June 96
Genetic Susceptibility
study released.
GLIAL CELLS
2/18/97 Within two years, predicts Ian Duncan, a professor at the
University of Wisconsin School of Veterinary Medicine, it may be possible to
repair lesions by injecting myelin-producing Glial Cells into patients' spinal
cords.
2/6/97 Glial cells
found to signal.
HELSINKI
Declaration of Helsinki
Recommendations guiding physicians in biomedical research involving human
subjects. Adopted by the 18th World Medical Assembly, Helsinki Finland, June
1964 amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975 35th
World Medical Assembly, Venice, Italy, October 1983 and the 41st World Medical
Assembly, Hong Kong, September 1989.
HEPATITIS B VACCINE
6/14/99 It is apparent that Critical Medical Decisions for
an entire generation of
American children are being made by small committees
whose members have
incestuous ties with agencies that stand to gain power, or
manufacturers that stand to gain enormous profits, from the policy that is
made.
8/18/98 Reports linking Hepatitis B vaccination to multiple
sclerosis are is not confirmed. Studies are being conducted in the US and
Europe.
1/9/97 We are trying to identify more patients with autoimmune
disorders that might be related to the Hepatitis B Vaccine in order to find
a better way to prevent, diagnose, and treat such reactions. Since it is clearly
established that this vaccine (or the virus infection istself) may cause MS like
symptoms, your information could be a great help for our ongoing
research.
HERPES
10/19/98 Have they found a Viral Link to MS? Dr.
Konstance K. Knox of the Institute for Viral Pathogenesis in Milwaukee,
Wisconsin, and colleagues at the American Neurological Association report a
study may point in that direction. Knox said "the study cannot
conclusively determine whether HHV-6 is a cause or effect of the
disease."
11/24/97 Specualtion: A strain of Reactivated Herpes virus may
be associated with multiple sclerosis (MS), an autoimmune disorder in which the
body attacks its own tissues.
6/97 Speculation: HHV-6
2/97 (3/96) Abstract: ACYCLOVIR treatment of
relapsing-remitting multiple sclerosis.
11/96 Abstract: HHV-6.
Subacute leukoencephalitis caused by CNS infection with human herpesvirus-6
manifesting as acute multiple sclerosis.
Also see: Viruses / Bacteria (below)
Hu23F2G
7/23/98 ICOS tests their monoclonal antibody Hu23F2G for safety and efficacy in
treating acute exacerbations in relapsing remitting r secondary-progressive
MS.
Ibuprofen
06/99 ST. PAUL, MN -- Ibuprofen has been shown to reduce
the "flu-like" side effects of the drug interferon beta-1b, an effective
treatment for multiple sclerosis attacks, according to a study in the June issue
of Neurology, the scientific journal of the American Academy of
Neurology.
IGE
10/96 Regulation of disease susceptibility: decreased prevalence of IgE-mediated allergic disease in
patients with multiple sclerosis. June 96
IgG IVIG
7/99 Administration of high-dose intravenous immunoglobulins has
become
one of the most successful new treatment regimens for
demyelinating
diseases.
4/98 In an attempt to prevent exacerbations of multiple sclerosis, Immunoglobulin Therapy was
combined with azathioprine (AZA). Intravenous immunoglobulin (i.v.IG) 2 g/kg was
given in divided doses over 3 consecutive days followed by monthly booster doses
(0.2 g/kg) for 3 years to 38 patients with relapsing-remitting multiple
sclerosis (MS).
7/98 IgG and
MS. Medline Abstract
IMMUNIZATIONS
3/10/97 Influenza
Vaccines can be safely administered to patients with multiple sclerosis,
according to an article in Neurology.
IMMUNOGLOBIN THERAPY
3/3/97 Monthly intravenous Immunoglobulin (IVIg) administration
to patients with relapsing-remitting multiple sclerosis (MS) improves "...the
course of clinical disability and reduce[s] the frequency of
relapses."
IMPANTABLE DRUG INFUSION
10/2/96 Thinner Implantable Drug Infusion system
cleared by FDA. Used in severe MS cases with baclofen.
INTERFERON -
ORAL
2/25/99 Calypte Biomedical Corp. said Thursday its partly owned
affiliate, Pepgen Corp., will begin Phase I clinical trials of its oral
interferon, Interferon Tau, in multiple
sclerosis patients.
IRON
Be sure to visit Bobby's website on researching Hereditary Biochemcial Multiple
Sclerosis
